Niacin as antidyslipidemic drug

被引:34
|
作者
Julius, Ulrich [1 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Internal Med 3, D-01307 Dresden, Germany
关键词
niacin; lipid disorders; intervention studies; cardiovascular end-points; adverse effects; EXTENDED-RELEASE NIACIN; LOW HDL/HIGH TRIGLYCERIDES; TRIAL ATHEROTHROMBOSIS INTERVENTION; APOLIPOPROTEIN-A-I; NICOTINIC-ACID; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; COMBINATION THERAPY; FATTY LIVER; LIPOPROTEIN(A) CONCENTRATION;
D O I
10.1139/cjpp-2014-0478
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Niacin is an important vitamin (B3) that can be used in gram doses to positively modify pathogenetically relevant lipid disorders: elevated LDL cholesterol, elevated non-HDL cholesterol, elevated triglycerides, elevated lipoprotein(a), and reduced HDL cholesterol. This review reports the latest published findings with respect to niacin's mechanisms of action on these lipids and its anti-inflammatory and anti-atherosclerotic effects. In the pre-statin era, niacin was shown to have beneficial effects on cardiovascular end-points; but in recent years, two major studies performed in patients whose LDL cholesterol levels had been optimized by a statin therapy did not demonstrate an additional significant effect on these end-points in the groups where niacin was administered. Both studies have several drawbacks that suggest that they are not representative for other patients. Thus, niacin still plays a role either as an additive to a statin or as a substitute for a statin in statin-intolerant patients. Moreover, patients with elevated triglyceride and low HDL cholesterol levels and patients with elevated lipoprotein(a) concentrations will possibly benefit from niacin, although currently the study evidence for these indications is rather poor. Niacin may be useful for compliant patients, however possible side effects (flushing, liver damage) and contraindications should be taken into consideration.
引用
收藏
页码:1043 / 1054
页数:12
相关论文
共 50 条
  • [1] THE MECHANISM OF CATECHIN AS ANTIDYSLIPIDEMIC DRUG (IN SILICO STUDY)
    Adelina, Rosa
    Kurniatri, Arifayu Addiena
    BULETIN PENELITIAN KESEHATAN, 2018, 46 (03): : 147 - 154
  • [2] USE OF NIACIN AS A DRUG
    DIPALMA, JR
    THAYER, WS
    ANNUAL REVIEW OF NUTRITION, 1991, 11 : 169 - 187
  • [3] Repurposing Niacin as Antiplatelet Drug?
    Mangoni, Arduino A.
    CURRENT CLINICAL PHARMACOLOGY, 2016, 11 (01): : 2 - +
  • [4] Niacin: An old drug rejuvenated
    Vaijinath S. Kamanna
    Shobha H. Ganji
    Moti L. Kashyap
    Current Atherosclerosis Reports, 2009, 11
  • [5] Niacin: An Old Drug Rejuvenated
    Kamanna, Vaijinath S.
    Ganji, Shobha H.
    Kashyap, Moti L.
    CURRENT ATHEROSCLEROSIS REPORTS, 2009, 11 (01) : 45 - 51
  • [6] Drug use evaluation of antidyslipidemic agents at a community hospital in Japan
    Ujita, K
    Ohno, K
    Hashiguchi, M
    Echizen, H
    Rikihisa, T
    Ogata, H
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2002, 122 (07): : 499 - 506
  • [7] CORONARY DRUG PROJECT - EXPERIENCE WITH NIACIN
    BERGE, KG
    CANNER, PL
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 : S49 - S51
  • [8] Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?
    Kobayashi, Yusuke
    Banno, Kouji
    Kunitomi, Haruko
    Nagai, Shimpei
    Takahashi, Takayuki
    Anko, Mayuka
    Iijima, Moito
    Takeda, Takashi
    Matoba, Yusuke
    Nakamura, Kanako
    Tsuji, Kosuke
    Tominaga, Eiichiro
    Aoki, Daisuke
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2019, 28 (06) : 562 - 567
  • [9] Should niacin be the preferred drug to add to a statin?
    Davidson M.H.
    Current Cardiology Reports, 2010, 12 (6) : 447 - 449
  • [10] Niacin is Major Drug for Lowering LDL - Cholesterol
    Murad, Shah
    Memon, M. Ashraf
    Channa, M. Aslam
    Kafil, Nighat
    Turab, S. Mohsin
    Bhurgri, Ghulam Rasool
    Rasheed, Shahzad
    Chohan, Raj Kumar
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2008, 2 (03): : 104 - 106